Fig. 3. Systemic pretreatment with Tat-PSD-95 PDZ2 significantly reduced halothane minimum alveolar concentration (MAC). Halothane MAC was measured after intraperitoneal injection of Tat-PSD-95 PDZ2 (n = 8), mutated Tat-PSD-95 PDZ2 (n = 8), and PSD-95 PDZ2 without Tat (n = 6). Note that Tat-PSD-95 PDZ2 dose-dependently reduced halothane MAC. However, mutated Tat-PSD-95 PDZ2 and PSD-95 PDZ2 had no effect. * P < 0.05 versus vehicle group.